biote vs Lifevantage
BTMD and LFVN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BTMD and LFVN compare
Lifevantage is the larger company, worth 1.6 times as much as biote ($62.3M against $38.3M).
biote grew revenue faster over the last twelve months (−8.6% versus −24.8% for Lifevantage).
Lifevantage keeps more of each dollar of sales as profit, with a net margin of 1.6% compared with −1.1% at biote.
Lifevantage pays a dividend yielding 3.8%; biote does not pay one.
Lifevantage scores higher on the StockData Score (16 against 4 for biote), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BTMD | LFVN |
|---|---|---|
| Size and price | ||
| Market cap | $38.3M | $62.3M |
| Share price | $1.06 | $4.97 |
| Change, 1 year | −59.7% | −25.2% |
| Change, 5 years | −89.1% | −32.7% |
| Beta (5Y) | 0.51 | 0.38 |
| Employees | 223 | 223 |
| StockData Score | ||
| Total score | 4 | 16 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 23.7× |
| P/S | 0.2× (better) | 0.4× |
| P/B | – | 1.9× |
| EV/EBITDA | 12.2× | 7.4× (better) |
| P/FCF | 5.2× (better) | 7.2× |
| PEG | – | 0.91 |
| FCF yield | 19.4% (better) | 14.0% |
| Fair value | – | $6.48 |
| Margin of safety | – | 23.3% |
| Growth | ||
| Revenue growth (TTM) | −8.6% (better) | −24.8% |
| Revenue growth, 5Y average | – | −3.7% |
| Net income growth (TTM) | −107% | −73.1% (better) |
| EPS growth (TTM) | −114% | −72.7% (better) |
| EPS growth, 5Y average | – | −15.0% |
| Profitability | ||
| Gross margin | 67.5% | 76.5% (better) |
| Operating margin | 5.0% (better) | 2.1% |
| Net margin | −1.1% | 1.6% (better) |
| FCF margin | 4.1% | 5.1% (better) |
| Return on equity | – | 8.2% |
| Return on invested capital | 18.5% (better) | 14.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 8.62 | – |
| Current ratio | 1.37 | 1.91 (better) |
| Altman Z-score | 1.65 | 2.42 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 3.8% |
| Payout ratio | – | 88.2% |
| Years of dividend growth | – | 1 |
| Buyback yield | 18.9% (better) | 2.4% |
| Shareholder yield | 18.9% (better) | 6.2% |
| Ownership | ||
| Held by institutions | 36.6% | 47.2% |
| Held by insiders | 23.3% | 27.8% |
| Insider net buying, 12 months | $202K (better) | $54.8K |
| Short interest, % of float | 3.1% | 10.0% |
Go deeper
- BTMD stock overview
- BTMD income statement
- BTMD valuation and score
- LFVN stock overview
- LFVN income statement
- LFVN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.